Consolidated Statements of Operations - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Consolidated Statements of Operations
Revenue	$ 1,228	$ 787
Operating expenses:
General and administrative	7,586	7,405
Research and development	16,924	19,119
Total operating expenses	24,510	26,524
Loss from operations	(23,282)	(25,737)
Change in fair value of warrant liability	(1,597)	(1,628)
Other income, net	1,151	30
Net (loss) before income taxes	(20,534)	(24,079)
Income tax (benefit) expense	(124)	13
Net loss	(20,410)	(24,092)
Net gain attributable to non-controlling interest	(163)
Net loss attributable to Onconova Therapeutics, Inc.	$ (20,573)	$ (24,092)
Net loss per share of common stock, basic and diluted (in dollars per share)	$ (4.99)	$ (40.15)
Basic and diluted weighted average shares outstanding (in shares)	4,124,073	600,022